m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0012)
Name |
Oral cavity/oesophagus/stomach in situ carcinoma
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 2E60
|
Full List of Target Gene(s) of This m6A-centered Disease Response
Collagenase 3 (MMP13)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | Up-regulation of FTO is frequently observed in esophageal squamous cell carcinoma tissues, and FTO facilitates cell proliferation and migration in ESCC by up-regulating Collagenase 3 (MMP13). | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell growth and migration | |||
In-vitro Model | Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
In-vivo Model | Stable down-regulated FTO cells were prepared in Eca-109 and KYSE150 and subcutaneously injected into the flank of nude mouse with 2 × 106 cells per mouse. | |||
Cyclin-dependent kinase inhibitor 1 (CDKN1A)
In total 4 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | YTH domain-containing protein 2 (YTHDC2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
NF-kappa B signaling pathway | hsa04064 | |||
JAK-STAT signaling pathway | hsa04630 | |||
Cell Process | Genetic variants | |||
In-vitro Model | KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | Expression of CDKN1A (p21) was significantly up-regulated in ALKBH5-depleted cells, and m6 A modification and stability of Cyclin-dependent kinase inhibitor 1 (CDKN1A) mRNA were increased by ALKBH5 knockdown. Identify ALKBH5 as the first m6 A demethylase that accelerates cell cycle progression and promotes cell proliferation of ESCC cells, which is associated with poor prognosis of esophageal squamous cell carcinoma patients. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Cell cycle | hsa04110 | ||
Cell Process | Cell cycle | |||
Cell apoptosis | ||||
In-vitro Model | OE21 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_2661 |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
TE-5 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1764 | |
TE-9 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1767 | |
In-vivo Model | The OE21 cells were stably transfected with sh-ALKBH5 (#1), sh-ALKBH5 (#2) or sh-scramble as negative control and injected (2 × 106 cells/mouse in 100 uL volume) subcutaneously into the back of male athymic BALB/c nude mice (6 weeks old, Japan SLC). | |||
Experiment 3 Reporting the m6A-centered Disease Response by This Target Gene | [4] | |||
Response Summary | The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of LINC00022 transcript, leading to the inhibition of LINC00022 decay via the m6A reader YTHDF2. LINC00022 directly binds to Cyclin-dependent kinase inhibitor 1 (CDKN1A) protein and promotes its ubiquitination-mediated degradation, thereby facilitating cell-cycle progression and proliferation. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Pathway Response | Cell cycle | hsa04110 | ||
Ubiquitin mediated proteolysis | hsa04120 | |||
Cell Process | Ubiquitination degradation | |||
Cell apoptosis | ||||
Decreased G0/G1 phase | ||||
In-vitro Model | HET-1A | Normal | Homo sapiens | CVCL_3702 |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
KYSE-450 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1353 | |
KYSE-70 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
In-vivo Model | The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively. | |||
Experiment 4 Reporting the m6A-centered Disease Response by This Target Gene | [5] | |||
Response Summary | METTL3 modulates the cell cycle of Esophageal squamous cell carcinoma(ESCC) cells through a Cyclin-dependent kinase inhibitor 1 (CDKN1A)-dependent pattern. METTL3-guided m6A modification contributes to the progression of ESCC via the p21-axis. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | Cell cycle | hsa04110 | ||
Cell Process | Arrest cell cycle at G2/M phase | |||
In-vitro Model | TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
In-vivo Model | Totally 5 × 106 ESCC cells after treatment were administered to randomized animals by the subcutaneous route (right flank) in 200 uL DMEM. Tumor measurement was performed every other day. At study end (at least 3 weeks), the animals underwent euthanasia, and the tumors were extracted for histology. | |||
G1/S-specific cyclin-D2 (CCND2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | YTH domain-containing protein 2 (YTHDC2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
NF-kappa B signaling pathway | hsa04064 | |||
JAK-STAT signaling pathway | hsa04630 | |||
Cell Process | Genetic variants | |||
In-vitro Model | KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
L-glutamine amidohydrolase (GLS2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [6] | |||
Response Summary | L-glutamine amidohydrolase (GLS2) as a downstream target of METTL3. These findings uncover METTL3/GLS2 signaling as a potential therapeutic target in antimetastatic strategies against esophageal Squamous Cell Carcinoma(ESCC). | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell migration | |||
Cell invasion | ||||
In-vitro Model | HEEC cell line (Normal esophageal epithelial cell line) | |||
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
TE-13 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_4463 | |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
EC/CUHK1 | Esophageal carcinoma | Homo sapiens | CVCL_RY08 | |
Mammalian target of rapamycin complex 2 (mTORC2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [7] | |||
Response Summary | ALKBH5 as a demethylase was lowly expressed in cancer progression of esophageal squamous cell carcinoma (ESCC) and acts as a crucial component in ESCC progression. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | ||
Cell Process | Cell proliferation and invasion | |||
In-vitro Model | KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
Microprocessor complex subunit DGCR8 (DGCR8)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | METTL3 could interact with Microprocessor complex subunit DGCR8 (DGCR8) protein and positively modulate pri-miR-320b maturation process in an N6-methyladenosine (m6A)-dependent manner. Therefore, our findings uncover a VEGF-C-independent mechanism of exosomal and intracellular miR-320b-mediated LN metastasis and identify miR-320b as a novel predictive marker and therapeutic target for LN metastasis in ESCC. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
Epithelial-mesenchymal transition | ||||
In-vitro Model | TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
HET-1A | Normal | Homo sapiens | CVCL_3702 | |
CVCL_E307 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
In-vivo Model | Luciferase-labeled KYSE150 cells (5 × 106) were inoculated into the footpads of BALB/c nude mice (4-5 weeks old, 18-20 g) to establish the popliteal lymphatic metastasis model. | |||
Neurogenic locus notch homolog protein 1 (NOTCH1)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [9] | |||
Response Summary | METTL3-catalyzed m6A modification promotes Neurogenic locus notch homolog protein 1 (NOTCH1) expression and the activation of the Notch signaling pathway. Forced activation of Notch signaling pathway successfully rescues the growth, migration, and invasion capacities of METTL3-depleted ESCC cells. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Notch signaling pathway | hsa04330 | ||
Cell Process | Cell migration | |||
Cell invasion | ||||
In-vitro Model | TE-9 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1767 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
In-vivo Model | For induction of ESCC, 4-week-old mice were treated with drinking water containing 50 ug/mL 4NQO (Sigma-Aldrich, USA) for 16 weeks and then given normal drinking water for another 4-5 weeks. Cre was activated by the intraperitoneal injection of tamoxifen (Sigma-Aldrich, USA) at a dose of 9 mg per 40 g body weight every other day for a total of three injections. For tumor measurement, mice were sacrificed, and the esophagus was dissected immediately. The surface areas of tumors were measured as described previously. | |||
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [10] | |||
Response Summary | Knockdown of FTO drastically suppressed the proliferation, migration, and invasion of ESCC cells,and Receptor tyrosine-protein kinase erbB-2 (ERBB2) is the target of FTO, which acts in concert in ESCC tumorigenesis and metastasis. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
In-vitro Model | KYSE-450 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1353 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
KYSE-180 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1349 | |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
KYSE-140 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1347 | |
In-vivo Model | For the subcutaneous transplantation model, sh-control, sh-FTO, NC-OE and ERBB2-OE KYSE150 stable cells (6 × 106 per mouse, n = 3 for each group) were diluted to 100 uL PBS + 100 uL Matrigel (BD) and subcutaneously injected to two points in the middle and upper groin of immunodeficient mice to study tumor growth. When the tumor volume reached ~ 1000 mm3 in each group, the nude mice were killed, and the tumors were excised and weighed for histology and further study. The tumor volume was calculated by the formula V = 1/2 × large diameter × (small diameter)2. For a model of lung metastasis in vivo, nude mice were injected with 100 uL WT (wide type), sh-FTO, ERBB2-OE and sh-FTO+ERBB2-OE KYSE150 stable cells (1 × 106 cells per mouse, n = 3 for each group) through tail vein, respectively. Six weeks after injection, the mice were killed and analyzed for metastatic lung tumors. | |||
Transforming growth factor beta-2 proprotein (TGFB2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | YTH domain-containing protein 2 (YTHDC2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | p53 signaling pathway | hsa04115 | ||
NF-kappa B signaling pathway | hsa04064 | |||
JAK-STAT signaling pathway | hsa04630 | |||
Cell Process | Genetic variants | |||
In-vitro Model | KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
Tribbles homolog 2 (TRIB2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [11] | |||
Response Summary | METTL14, an m6A RNA methyltransferase downregulated in ESCC, suppresses Tribbles homolog 2 (TRIB2) expression via miR-99a-5p-mediated degradation of TRIB2 mRNA by targeting its 3' untranslated region, whereas TRIB2 induces ubiquitin-mediated proteasomal degradation of METTL14 in a COP1-dependent manner. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Proteasome pathway degradation | |||
In-vitro Model | TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 |
KYSE-410 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1352 | |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
HET-1A | Normal | Homo sapiens | CVCL_3702 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
CVCL_E307 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
In-vivo Model | Fresh PDX tumor samples collected from two established PDX models (PDX #07 with high TRIB2 expression and PDX #12 with low TRIB2, passages three to four) were minced and subcutaneously implanted into the flanks of 3- to 4-week-old female BALB/c nude mice (Jiesijie Laboratory Animals). | |||
Deleted in lymphocytic leukemia 2 (DLEU2/LINC00022)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [4] | |||
Response Summary | The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of LINC00022 transcript, leading to the inhibition of Deleted in lymphocytic leukemia 2 (DLEU2/LINC00022) decay via the m6A reader YTHDF2. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | Cell cycle | hsa04110 | ||
Ubiquitin mediated proteolysis | hsa04120 | |||
Cell Process | Ubiquitination degradation | |||
Cell apoptosis | ||||
Decreased G0/G1 phase | ||||
In-vitro Model | HET-1A | Normal | Homo sapiens | CVCL_3702 |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
KYSE-450 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1353 | |
KYSE-70 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
In-vivo Model | The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [4] | |||
Response Summary | The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of Deleted in lymphocytic leukemia 2 (DLEU2/LINC00022) transcript, leading to the inhibition of LINC00022 decay via the m6A reader YTHDF2. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Cell cycle | hsa04110 | ||
Ubiquitin mediated proteolysis | hsa04120 | |||
Cell Process | Ubiquitination degradation | |||
Cell apoptosis | ||||
Decreased G0/G1 phase | ||||
In-vitro Model | HET-1A | Normal | Homo sapiens | CVCL_3702 |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
KYSE-450 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1353 | |
KYSE-70 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1356 | |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
In-vivo Model | The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively. | |||
Long intergenic non-protein coding RNA 278 (LINC00278)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [12] | |||
Response Summary | Downregulation of YY1BM significantly upregulated eEF2K expression and inhibited apoptosis, thus conferring esophageal squamous cell carcinoma cells more adaptive to nutrient deprivation. Cigarette smoking decreased m6A modification of Long intergenic non-protein coding RNA 278 (LINC00278) and YY1BM translation. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Cell Process | Nutrient deprivation | |||
Cell apoptosis | ||||
In-vitro Model | HEK293T | Normal | Homo sapiens | CVCL_0063 |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
HET-1A | Normal | Homo sapiens | CVCL_3702 | |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 | |
In-vivo Model | Injected YY1BM intratumorally into ESCC tumors grafted in nude mice and analyzed the survival time. | |||
hsa-miR-320b
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [8] | |||
Response Summary | METTL3 could interact with DGCR8 protein and positively modulate pri-miR-320b maturation process in an N6-methyladenosine (m6A)-dependent manner. Therefore, our findings uncover a VEGF-C-independent mechanism of exosomal and intracellular hsa-miR-320b-mediated LN metastasis and identify miR-320b as a novel predictive marker and therapeutic target for LN metastasis in ESCC. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | PI3K-Akt signaling pathway | hsa04151 | ||
Cell Process | Cell proliferation | |||
Cell migration | ||||
Cell invasion | ||||
Epithelial-mesenchymal transition | ||||
In-vitro Model | TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 |
KYSE-30 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1351 | |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
HET-1A | Normal | Homo sapiens | CVCL_3702 | |
CVCL_E307 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
In-vivo Model | Luciferase-labeled KYSE150 cells (5 × 106) were inoculated into the footpads of BALB/c nude mice (4-5 weeks old, 18-20 g) to establish the popliteal lymphatic metastasis model. | |||
hsa-miR-99a-5p
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [11] | |||
Response Summary | METTL14, an m6A RNA methyltransferase downregulated in ESCC, suppresses TRIB2 expression via hsa-miR-99a-5p-mediated degradation of TRIB2 mRNA by targeting its 3' untranslated region, whereas TRIB2 induces ubiquitin-mediated proteasomal degradation of METTL14 in a COP1-dependent manner. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Ubiquitin mediated proteolysis | hsa04120 | ||
Cell Process | Proteasome pathway degradation | |||
In-vitro Model | TE-1 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1759 |
KYSE-410 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1352 | |
KYSE-150 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_1348 | |
HET-1A | Normal | Homo sapiens | CVCL_3702 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_6898 | |
CVCL_E307 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_E307 | |
In-vivo Model | Fresh PDX tumor samples collected from two established PDX models (PDX #07 with high TRIB2 expression and PDX #12 with low TRIB2, passages three to four) were minced and subcutaneously implanted into the flanks of 3- to 4-week-old female BALB/c nude mice (Jiesijie Laboratory Animals). | |||
Circ_SLC7A5
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [13] | |||
Response Summary | the biological characteristics of Circ_SLC7A5 including location, miRNAs binding, m6A modification were analyzed. Our study reveals a novel prognosis biomarker of circ-SLC7A5, providing a preliminary landscape of circRNA expression for detection of esophageal squamous cell carcinoma. | |||
Responsed Disease | Esophageal squamous cell carcinoma [ICD-11: 2B70.1] | |||
In-vitro Model | () | |||
K150 (Esophageal squamous cell carcinoma) | ||||
K150 (Esophageal squamous cell carcinoma) | ||||
K150 (Esophageal squamous cell carcinoma) | ||||
K150 (Esophageal squamous cell carcinoma) | ||||
K150 (Esophageal squamous cell carcinoma) | ||||
T10 | Esophageal squamous cell carcinoma | Homo sapiens | CVCL_RL56 | |
T12 (Human ESCC cell line) | ||||
References